Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Other

November 20, 2020

Imeglimin Ph3 US and EU Development Discontinued by Metavant; Poxel Seeks Other Options

Here is a brief preview of this blast: Poxel announced that Metavant, its US and EU development partner for Imeglimin, has decided not to move Imeglimin into Ph3 trials. Recall, in Poxel's Q3 '20 earnings update, Poxel disclosed that Metavant was in discussions with FDA regarding the Imeglimin Ph3 program in patients with T2DM and stage 3b or 4 CKD (previous FENIX insight). Below, FENIX provides thoughts on the future of Imeglimin in Western markets.